Amgen Inc. buy melinda
Start price
31.08.17
/
50%
€176.34
Target price
12.09.17
€190.00
Performance (%)
7.96%
End price
12.09.17
€190.38
Summary
This prediction ended on 12.09.17 with a price of €190.38. The BUY prediction by melinda finished with a performance of 7.96%. melinda has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Amgen Inc. | -0.281% | -0.281% | 20.096% | 43.989% |
| iShares Core DAX® | 0,88 % | 1,05 % | 7,09 % | 54,45 % |
| iShares Nasdaq 100 | 0,75 % | 4,66 % | 41,85 % | 95,49 % |
| iShares Nikkei 225® | 5,52 % | 15,41 % | 73,76 % | 85,82 % |
| iShares S&P 500 | 0,24 % | 1,68 % | 27,53 % | 69,02 % |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
$
Wenn in Phase III getestet Kopf an Kopf, das Bestreben, reduziert KYPROLIS und Dexamethason das Sterberisiko um 21% und erhöhte die Überlebenszeit von 7,6 Monaten im Vergleich zu Velcade und Dexamethason in Patienten mit rezidivierendem oder refraktärem multiplem Myelom